Previous Close | 0.1000 |
Open | 0.1000 |
Bid | 0.0500 |
Ask | 0.1500 |
Strike | 3.50 |
Expire Date | 2025-01-17 |
Day's Range | 0.1000 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 149 |
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor progression and chemotherapy resistance. Researchers also found that OGM was a
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2023 Earnings Call Transcript March 5, 2024 Bionano Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.96 EPS, expectations were $-0.87. Bionano Genomics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical genome mapping (OGM) and findings from early access customersThe pre-conference event will also include a 2024 corporate overview from Bionano’s chief executive officer, Dr. Erik Holmlin, presentations from Dr. Brynn Levy at Columbia University Medical Center, Dr. Ulrich Broeckel at Medical College of Wisconsin, Dr. Susan Crocker at Kingston Heal